Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation

Inclusion Criteria

• •Patient´s written informed consent
• •≥ 18 years of age; male and female
• •Confirmed CLL, low grade NHL or high grade NHL on standard histological or immunophenotypical criteria described in the WHO classification of lymphoid malignancies
• •CD20 positivity (if not already confirmed)
• •Adequate haematological, liver and kidney functions
• •Platelet count ≥25,000mm³ (=25 x 10\^9/l)
• •Patients with active disease (relapsed/refractory) that survived at least 60 days after allogeneic transplantation
• •Eastern Cooperative Oncology Group (ECOG) performance status \<=2 (Appendix IV)
• •Negative pregnancy test (no more than 2 days before enrolment) and adequate contraception during the study in women of child bearing potential (pre- menopausal, \<2 years post-menopausal or not surgically sterile)